Commentary: Case Report: Lenvatinib for the treatment of recurrent hepatocellular carcinoma in people living with HIV: a report of two cases.
作者信息
Sun Cuiming, Wen Ying, Zhou Jin
机构信息
The Second Department of Infectious Disease, The First Hospital of China Medical University, Shenyang, China.
Medical Oncology Department of Gastrointestinal Cancer, Liaoning Cancer Hospital Institute, Cancer Hospital of Dalian University of Technology, Shenyang, China.
出版信息
Front Oncol. 2024 Apr 5;14:1372745. doi: 10.3389/fonc.2024.1372745. eCollection 2024.
Abstract
摘要
相似文献
1
Commentary: Case Report: Lenvatinib for the treatment of recurrent hepatocellular carcinoma in people living with HIV: a report of two cases.评论：病例报告：乐伐替尼用于治疗HIV感染者复发性肝细胞癌：两例报告
Front Oncol. 2024 Apr 5;14:1372745. doi: 10.3389/fonc.2024.1372745. eCollection 2024.
2
Case Report: Lenvatinib for the treatment of recurrent hepatocellular carcinoma in people living with HIV: a report of two cases.病例报告：乐伐替尼治疗HIV感染者复发性肝细胞癌：两例报告
Front Oncol. 2023 Dec 5;13:1242741. doi: 10.3389/fonc.2023.1242741. eCollection 2023.
3
Efficacy and Safety of Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Report of Two Cases.仑伐替尼治疗活体肝移植后复发性肝细胞癌的疗效和安全性：两例报告。
Anticancer Res. 2022 Feb;42(2):1161-1167. doi: 10.21873/anticanres.15581.
4
Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma.专家共识：仑伐替尼治疗肝细胞癌不良反应的管理。
J Gastroenterol Hepatol. 2022 Mar;37(3):428-439. doi: 10.1111/jgh.15727. Epub 2021 Nov 17.
5
Potential Role of Adjuvant Lenvatinib in Improving Disease-Free Survival for Patients With High-Risk Hepatitis B Virus-Related Hepatocellular Carcinoma Following Liver Transplantation: A Retrospective, Case Control Study.辅助性乐伐替尼在改善高危乙型肝炎病毒相关肝细胞癌肝移植术后患者无病生存期方面的潜在作用：一项回顾性病例对照研究
Front Oncol. 2020 Dec 7;10:562103. doi: 10.3389/fonc.2020.562103. eCollection 2020.
6
Efficient multiple treatments including molecular targeting agents in a case of recurrent hepatocellular carcinoma, post-living donor liver transplantation.在一例活体肝移植后复发性肝细胞癌的病例中，采用了多种有效的治疗方法，包括分子靶向药物。
Clin J Gastroenterol. 2022 Aug;15(4):755-764. doi: 10.1007/s12328-022-01643-3. Epub 2022 May 30.
7
Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study.乐伐替尼在肝移植肝细胞癌患者中的疗效与安全性：一项病例对照研究
Cancers (Basel). 2021 Sep 12;13(18):4584. doi: 10.3390/cancers13184584.
8
Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report.乐伐替尼治疗后复发性肝细胞癌的成功肝切除术：一例报告
World J Hepatol. 2020 Dec 27;12(12):1349-1357. doi: 10.4254/wjh.v12.i12.1349.
9
Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability toward Adverse Events.周末停用乐伐替尼治疗不可切除肝细胞癌可改善治疗反应及对不良事件的耐受性。
Cancers (Basel). 2020 Apr 19;12(4):1010. doi: 10.3390/cancers12041010.
10
The efficacy and safety of lenvatinib plus transarterial chemoembolization in combination with PD-1 antibody in treatment of unresectable recurrent hepatocellular carcinoma: a case series report.乐伐替尼联合经动脉化疗栓塞术与PD-1抗体治疗不可切除复发性肝细胞癌的疗效及安全性：病例系列报告
Front Oncol. 2023 May 16;13:1096955. doi: 10.3389/fonc.2023.1096955. eCollection 2023.
本文引用的文献
1
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib.乐伐替尼治疗肝细胞癌患者食管胃静脉曲张出血的发生率及预测因素
Liver Cancer. 2023 Sep 14;13(2):215-226. doi: 10.1159/000534127. eCollection 2024 Apr.
2
Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study.REFLECT 研究中仑伐替尼治疗肝细胞癌患者出现治疗后高血压与生存的关系。
Cancer. 2024 Apr 15;130(8):1281-1291. doi: 10.1002/cncr.35185. Epub 2024 Jan 23.
3
Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.瑞戈非尼联合免疫检查点抑制剂疗法作为晚期肝细胞癌患者二线和三线治疗方案的疗效与安全性：一项回顾性研究
J Gastrointest Oncol. 2023 Dec 31;14(6):2549-2558. doi: 10.21037/jgo-23-590. Epub 2023 Dec 27.
4
Efficacy of lenvatinib sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta-analysis.乐伐替尼与索拉非尼在晚期肝细胞癌一线治疗中的疗效：一项荟萃分析。
JGH Open. 2023 Dec 13;7(12):832-840. doi: 10.1002/jgh3.12999. eCollection 2023 Dec.
5
Case Report: Lenvatinib for the treatment of recurrent hepatocellular carcinoma in people living with HIV: a report of two cases.病例报告：乐伐替尼治疗HIV感染者复发性肝细胞癌：两例报告
Front Oncol. 2023 Dec 5;13:1242741. doi: 10.3389/fonc.2023.1242741. eCollection 2023.
6
The safety and efficacy of PD-1 inhibitors in patients with advanced cancers and HIV/AIDS in China.在中国，PD-1抑制剂在晚期癌症和艾滋病毒/艾滋病患者中的安全性和疗效。
Front Oncol. 2023 Sep 19;13:1248790. doi: 10.3389/fonc.2023.1248790. eCollection 2023.
7
Efficacy and safety of lenvatinib-transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective study.仑伐替尼经导管动脉化疗栓塞序贯治疗联合手术切除治疗超 UCSF 标准 7 分的中期肝细胞癌的疗效和安全性：一项多中心、单臂、前瞻性研究的研究方案。
BMJ Open. 2023 Oct 5;13(10):e073797. doi: 10.1136/bmjopen-2023-073797.
8
Risk of hepatocellular carcinoma in people with HIV in the United States, 2001-2019.2001-2019 年美国 HIV 感染者罹患肝细胞癌的风险。
J Natl Cancer Inst. 2024 Jan 10;116(1):61-68. doi: 10.1093/jnci/djad172.
9
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.免疫检查点抑制剂在 HIV 感染者和癌症患者中的安全性和活性：来自癌症治疗中使用免疫检查点抑制剂的 HIV 感染者-国际（CATCH-IT）联盟的真实世界报告。
J Clin Oncol. 2023 Jul 20;41(21):3712-3723. doi: 10.1200/JCO.22.02459. Epub 2023 May 16.
10
Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation.仑伐替尼治疗肝移植后复发性肝细胞癌患者的疗效和安全性。
Cancer Med. 2023 Feb;12(3):2572-2579. doi: 10.1002/cam4.5123. Epub 2022 Aug 5.
Zotero 插件